Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
123 hedge funds and large institutions have $401M invested in Kezar Life Sciences in 2022 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 55 increasing their positions, 41 reducing their positions, and 19 closing their positions.
5,426% more call options, than puts
Call options by funds: $1.49M | Put options by funds: $27K
34% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 41
0.02% less ownership
Funds ownership: 8.42% → 8.4% (-0.02%)
7% less funds holding
Funds holding: 132 → 123 (-9)
16% less capital invested
Capital invested by funds: $480M → $401M (-$79.2M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
47% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$20.9M |
| 2 |
DM
Deerfield Management
New York
|
+$10.6M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$10.1M |
| 4 |
State Street
Boston,
Massachusetts
|
+$5.31M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$4.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$20.3M |
| 2 |
HM
HealthCor Management
New York
|
-$13.8M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$8.18M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$5M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$4.79M |
KZR Hedge Fund Activity: Q4 2022 in Review
123 of the 6,223 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q4 2022, worth a combined $401M — down 16% from $480M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of KZR and 10 opened new positions — a net loss of 9 holders — while 41 trimmed existing stakes and 55 added.
The largest buyer was OrbiMed, adding an estimated $20.9M. The largest seller was Victory Capital Management, exiting entirely with an estimated $20.3M sold.
- 123 institutional investors held Kezar Life Sciences (KZR) as of Q4 2022, down from 132 in Q3 2022.
- Funds reported $401M of Kezar Life Sciences stock for Q4 2022, down 16% quarter-over-quarter.
- 10 funds opened new Kezar Life Sciences positions in Q4 2022 and 19 closed out, a net change of -9 holders.
- The largest Kezar Life Sciences buyer in Q4 2022 was OrbiMed, an estimated $20.9M added.
- The largest Kezar Life Sciences seller in Q4 2022 was Victory Capital Management, an estimated $20.3M sold.
Based on aggregated 13F filings for Q4 2022.